MGC births first cannabis products into the UK
Health & Biotech
Health & Biotech
Special report: MGC Pharma has sent its first shipments of medical cannabis epilepsy treatment CannEpil to the UK.
MGC Pharmaceuticals’ (ASX:MXC) proprietary formulation is used to relieve symptoms such as seizures associated with severe epilepsy cases and that shipment has now arrived in the UK for distribution to pharmacies, or directly to medical patients.
“The first CannEpil shipment landing in the UK represents a true milestone in the history of MGC Pharma and the relief from symptoms of epilepsy,” said managing director Roby Zomer.
“The legalisation of medicinal cannabis passed in the UK only seven months ago, and the subsequent increasing interest in CannEpil leading to orders from medical professionals, is testament to the importance of our products into the fast-growing UK market, and beyond.
“Over half a million people in the UK suffer from epilepsy, and CannEpil has the potential to significantly enhance the lives of sufferers.”
Researcher Prohibition Partners estimates the value of the medicinal cannabis market in the UK in 2028 is €8.8bn.
CannEpil is an oral oil solution where conventional medicines and therapies have failed to control them. It was developed by MGC Pharma’s specialist R&D division which both grew the relevant cannabis strains and formulated the solution on the back of extensive and long-term observational studies.
Market Access specialists, Grow Biotech PLC and IPS Specials have received initial prescriptions in the UK for CannEpil.
Both companies provide direct, official access into the UK medical cannabis market with an extensive network of some 5,500 pharmacies.
MGC also makes CogniCann, which is specifically formulated for the relief of key dementia and Alzheimer’s symptoms, while InCann is for the relief from symptoms of Chron’s Disease and IBS.
TopiCann is a topical treatment to reduce psoriasis and eczema.
Recently, MGC signed two distribution and logistics agreements with Health House International, a wholesaler distributor of medicinal cannabis in Australia and the UK, and Cannvalate, a Melbourne-based med-cann company with operations across Australia and soon New Zealand and the UK.
While both deals give MGC extra access to Australia, their fledgling UK divisions should open extra doors in that country too.